DE3382764T2 - Humane-humane hybridomas für neoplasmen. - Google Patents
Humane-humane hybridomas für neoplasmen.Info
- Publication number
- DE3382764T2 DE3382764T2 DE3382764T DE3382764T DE3382764T2 DE 3382764 T2 DE3382764 T2 DE 3382764T2 DE 3382764 T DE3382764 T DE 3382764T DE 3382764 T DE3382764 T DE 3382764T DE 3382764 T2 DE3382764 T2 DE 3382764T2
- Authority
- DE
- Germany
- Prior art keywords
- human
- monoclonal antibodies
- cells
- fragments
- hybridomas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 51
- 206010028980 Neoplasm Diseases 0.000 title claims description 25
- 210000004027 cell Anatomy 0.000 claims abstract description 41
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- 230000004927 fusion Effects 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 15
- 208000019065 cervical carcinoma Diseases 0.000 claims description 12
- 210000001165 lymph node Anatomy 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 210000005170 neoplastic cell Anatomy 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 5
- 210000005260 human cell Anatomy 0.000 claims description 5
- 229940072221 immunoglobulins Drugs 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 230000007910 cell fusion Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000010893 malignant breast melanoma Diseases 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 9
- 201000009030 Carcinoma Diseases 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 abstract description 3
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 229940027941 immunoglobulin g Drugs 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000011799 hole material Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940098197 human immunoglobulin g Drugs 0.000 description 2
- 229940094342 human immunoglobulin m Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57084843A JPS58201994A (ja) | 1982-05-21 | 1982-05-21 | 抗原特異的ヒト免疫グロブリンの生産方法 |
| PCT/US1983/000781 WO1983004313A1 (en) | 1982-05-21 | 1983-05-20 | Human-human hybridomas for neoplasms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3382764D1 DE3382764D1 (de) | 1994-12-22 |
| DE3382764T2 true DE3382764T2 (de) | 1995-03-16 |
Family
ID=13842073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3382764T Expired - Lifetime DE3382764T2 (de) | 1982-05-21 | 1983-05-20 | Humane-humane hybridomas für neoplasmen. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0109441B1 (enExample) |
| JP (2) | JPS58201994A (enExample) |
| AT (1) | ATE114189T1 (enExample) |
| AU (1) | AU560595B2 (enExample) |
| CZ (1) | CZ280677B6 (enExample) |
| DE (1) | DE3382764T2 (enExample) |
| DK (1) | DK164510C (enExample) |
| FI (1) | FI86077C (enExample) |
| HU (1) | HU190908B (enExample) |
| IN (1) | IN157982B (enExample) |
| SK (1) | SK279249B6 (enExample) |
| WO (1) | WO1983004313A1 (enExample) |
| ZA (1) | ZA833686B (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247538A (en) * | 1982-05-21 | 1988-12-28 | Mark C. Glassy | Human-human hybridomas for solid tumors |
| US4618577A (en) * | 1983-02-09 | 1986-10-21 | The Regents Of The University Of California | Human-human hybridoma, CLNH5 |
| US4939240A (en) * | 1983-03-04 | 1990-07-03 | Health Research, Inc. | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
| ATE56046T1 (de) * | 1983-03-04 | 1990-09-15 | Health Research Inc | Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie. |
| US4613576A (en) * | 1983-03-09 | 1986-09-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cancer cells |
| US4693966A (en) * | 1983-03-11 | 1987-09-15 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies from lymphocytes of patients with malignant melanoma |
| GB2140030A (en) * | 1983-04-08 | 1984-11-21 | Kureha Chemical Ind Co Ltd | Monoclonal antibody to human urinary bladder cancer |
| EP0162070A1 (en) * | 1983-11-25 | 1985-11-27 | The University Of Melbourne | Cell line and monoclonal antibody |
| NZ210867A (en) * | 1984-01-31 | 1989-01-06 | Litton Bionetics Inc | Tumour-specific monoclonal antibodies, production thereof and use |
| DK144485A (da) * | 1984-03-30 | 1985-10-01 | Syntex Inc | Monoklonale antistoffer |
| US4886745A (en) * | 1984-03-30 | 1989-12-12 | Syntex Inc. | Monoclonal antibody specific for human basal cell surface antigen |
| JPS6133125A (ja) * | 1984-07-25 | 1986-02-17 | Morinaga & Co Ltd | ヒト単クロ−ン性抗肺ガン細胞抗体 |
| US4761377A (en) * | 1984-10-15 | 1988-08-02 | The Regents Of The University Of California | Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells |
| EP0183876A1 (en) * | 1984-11-27 | 1986-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal antibodies for endotoxin core and their use |
| US5106746A (en) * | 1985-05-22 | 1992-04-21 | E. I. Du Pont De Nemours And Company | Process for the in vitro immunization of human splenocytes against tumor associated antigens |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| JPH0655680B2 (ja) * | 1985-10-26 | 1994-07-27 | 萩原 義秀 | 悪性腫瘍用ヒトモノクロナル抗体複合剤 |
| EP0222360A3 (en) * | 1985-11-12 | 1989-03-15 | Biotherapeutics Inc. | A method of producing a patient-specific cytotoxic reagent and composition |
| JPH0767388B2 (ja) * | 1986-01-13 | 1995-07-26 | 三菱化学株式会社 | 抗体産生細胞株の樹立方法 |
| WO1991009135A1 (en) * | 1989-12-18 | 1991-06-27 | Board Of Regents, The University Of Texas System | Tumor-specific, cell surface-binding monoclonal antibodies |
| US5281710A (en) * | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
| JPH04346792A (ja) * | 1991-05-22 | 1992-12-02 | Hagiwara Yoshihide | 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列 |
| EP0528663B1 (en) * | 1991-08-16 | 1997-10-29 | Kabushiki Kaisha Toshiba | Monoclonal antibody to a synaptophysin |
| KR20090068385A (ko) | 1997-08-15 | 2009-06-26 | 츄가이 세이야꾸 가부시키가이샤 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
| TWI248365B (en) | 1999-08-23 | 2006-02-01 | Chugai Pharmaceutical Co Ltd | HM1.24 antigen expression potentiators |
| DE60045638D1 (de) | 1999-10-01 | 2011-03-31 | Chugai Pharmaceutical Co Ltd | Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen |
| WO2002064159A1 (fr) | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs affectant les organes hematopoietiques |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| WO2003068259A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| EP1541165A4 (en) | 2002-08-27 | 2009-06-24 | Chugai Pharmaceutical Co Ltd | METHOD FOR STABILIZING PROTEIN PREPARATION |
| DK1561756T3 (en) | 2002-09-11 | 2016-02-15 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR CLEANING PROTEIN. |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| US7863042B2 (en) | 2003-06-18 | 2011-01-04 | Chugai Seiyaku Kabushiki Kaisha | Fucose transporter |
| ATE528397T1 (de) | 2003-08-08 | 2011-10-15 | Perseus Proteomics Inc | Bei krebs überexprimiertes gen |
| JPWO2005054467A1 (ja) | 2003-12-03 | 2007-12-06 | 中外製薬株式会社 | 哺乳類βアクチンプロモーターを利用した発現系 |
| WO2005056605A1 (ja) | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | ３量体以上の受容体を認識する改変抗体 |
| UA94019C2 (ru) | 2004-07-09 | 2011-04-11 | Чугаи Сейяку Кабусики Кайся | Антитело, которое специфически связывается с глипиканом 3 (gpc3) |
| US20090061485A1 (en) | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
| EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| WO2006132363A1 (ja) | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | メグルミンを含有するタンパク質製剤の安定化剤、およびその利用 |
| CA2625773C (en) | 2005-10-14 | 2015-05-12 | Fukuoka University | Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation |
| JP5398987B2 (ja) | 2005-11-14 | 2014-01-29 | セルミド リミテッド | 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法 |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| AR057941A1 (es) | 2005-11-25 | 2007-12-26 | Univ Keio | Agentes terapeuticos para el cancer de prostata |
| CN104189907A (zh) | 2006-01-27 | 2014-12-10 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
| CN101479381B (zh) | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2654040T3 (es) | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos |
| JP5242382B2 (ja) | 2006-04-14 | 2013-07-24 | 株式会社医学生物学研究所 | エフェクター機能を有するポリペプチド変異体 |
| BRPI0712426B1 (pt) | 2006-06-08 | 2021-10-26 | Chugai Seiyaku Kabushiki Kaisha | Usos de um anticorpo anti-nr10/il-31ra com atividade neutralizante de nr10/il-31ra, de um fragmento e/ou um fragmento quimicamente modificado do anticorpo e de um agente |
| MX2008015975A (es) | 2006-06-14 | 2009-03-26 | Chugai Pharmaceutical Co Ltd | Agentes para promocionar el crecimiento de celulas de vastago hematopoyeticas. |
| WO2008007755A1 (en) | 2006-07-13 | 2008-01-17 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducer |
| JP5175729B2 (ja) | 2006-07-21 | 2013-04-03 | 中外製薬株式会社 | 腎疾患治療剤 |
| DE602006013809D1 (de) | 2006-07-24 | 2010-06-02 | Facultad De Medicina Universid | Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden |
| JP5317697B2 (ja) | 2006-08-14 | 2013-10-16 | 中外製薬株式会社 | 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 |
| WO2008032833A1 (en) | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| NZ576855A (en) | 2006-10-12 | 2012-08-31 | Forerunner Pharma Res Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody |
| AU2007311957A1 (en) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
| JP5618172B2 (ja) | 2007-01-05 | 2014-11-05 | 国立大学法人東京大学 | 抗ｐｒｇ−３抗体を用いる癌の診断および治療 |
| JP5374360B2 (ja) | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物 |
| EP2175016A4 (en) | 2007-06-25 | 2012-03-28 | Forerunner Pharma Res Co Ltd | ANTI-PROMININ-1 ANTIBODY WITH ADCC ACTIVITY OR CDC ACTIVITY |
| JP5424330B2 (ja) | 2007-07-26 | 2014-02-26 | 国立大学法人大阪大学 | インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤 |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| EP2196220B1 (en) | 2007-10-02 | 2014-12-03 | Chugai Seiyaku Kabushiki Kaisha | Inhibting anti-IL-6 receptor antibody for treating graft-versus-host disease |
| US20120047586A9 (en) | 2007-10-24 | 2012-02-23 | Otsuka Chemical Co., Ltd | Polypeptide having enhanced effector function |
| WO2009063970A1 (ja) | 2007-11-14 | 2009-05-22 | Forerunner Pharma Research Co., Ltd. | 抗gpr49抗体を用いる癌の診断および治療 |
| BRPI0820543A2 (pt) | 2007-11-15 | 2015-06-16 | Chugai Pharmaceutical Co Ltd | Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo |
| RU2541780C2 (ru) | 2007-12-05 | 2015-02-20 | Чугаи Сейяку Кабусики Кайся | Терапевтическое средство от зуда |
| BRPI0821110B8 (pt) | 2007-12-05 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo |
| US20110262425A1 (en) | 2007-12-12 | 2011-10-27 | National Cancer Center | Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| SG187457A1 (en) | 2008-01-11 | 2013-02-28 | Univ Tokyo | Anti-cldn6 antibody |
| HUE067049T2 (hu) | 2008-04-11 | 2024-09-28 | Chugai Pharmaceutical Co Ltd | Két vagy több antigén-molekulát ismétlõdõen megkötni képes antigénkötõ molekula |
| EP2116261A1 (en) | 2008-05-07 | 2009-11-11 | Institut Pasteur | Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof |
| US9226934B2 (en) | 2008-06-02 | 2016-01-05 | The University Of Tokyo | Anti-cancer drug |
| CN104906581A (zh) | 2008-06-05 | 2015-09-16 | 国立研究开发法人国立癌症研究中心 | 神经浸润抑制剂 |
| EP2319869B1 (en) | 2008-06-20 | 2016-08-17 | National University Corporation Okayama University | ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME |
| US20120014870A1 (en) | 2008-12-26 | 2012-01-19 | Forerunner Pharma Research Co., Ltd. | Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody |
| JP2010210772A (ja) | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| CA2760642A1 (en) | 2009-05-01 | 2010-11-04 | The University Of Tokyo | Anti-cadherin antibody |
| EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| SG10201404340TA (en) | 2009-07-31 | 2014-10-30 | Shin Maeda | Cancer metastasis inhibitor |
| TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| DK2535358T3 (en) | 2010-02-10 | 2018-02-05 | Fujifilm Ri Pharma Co Ltd | RADIOACTIVE METAL LABELED ANTI-CADHERINE ANTIBODY |
| JPWO2011105573A1 (ja) | 2010-02-26 | 2013-06-20 | 株式会社 未来創薬研究所 | 抗ｉｃａｍ３抗体およびその用途 |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| RS63800B1 (sr) | 2010-05-28 | 2022-12-30 | Chugai Pharmaceutical Co Ltd | Poboljšanje antitumorskog odgovora t ćelije |
| US9364505B2 (en) | 2010-10-25 | 2016-06-14 | Regents Of The University Of Minnesota | Therapeutic composition for treatment of glioblastoma |
| EP3708586A1 (en) | 2010-10-29 | 2020-09-16 | Perseus Proteomics Inc. | Anti-cdh3 antibody having high internalization capacity |
| US9574005B2 (en) | 2011-07-19 | 2017-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable Protein-containing preparation containing argininamide or analogous compound thereof |
| JP6101205B2 (ja) | 2011-08-23 | 2017-03-22 | 中外製薬株式会社 | 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体 |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| EP2772268B8 (en) | 2011-10-28 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
| KR102168733B1 (ko) | 2011-10-31 | 2020-10-23 | 추가이 세이야쿠 가부시키가이샤 | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 |
| KR20150003251A (ko) | 2012-04-04 | 2015-01-08 | 가부시키가이샤 페르세우스 프로테오믹스 | 항 cdh3(p-카드헤린) 항체의 약물 콘쥬게이트 |
| JP6519851B2 (ja) | 2012-07-06 | 2019-05-29 | 京都府公立大学法人 | 眼細胞の分化マーカーおよび分化制御 |
| HK1210500A1 (en) | 2012-09-27 | 2016-04-22 | 中外制药株式会社 | Fgfr3 fusion gene and pharmaceutical drug targeting same |
| EP3009518B1 (en) | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
| WO2015099127A1 (ja) | 2013-12-27 | 2015-07-02 | 中外製薬株式会社 | Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬 |
| EP3088411B1 (en) | 2013-12-27 | 2025-09-24 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying antibody having low isoelectric point |
| EP4056993A1 (en) | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| SG11201705093UA (en) | 2015-02-27 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Composition for treating il-6-related diseases |
| JP7050333B2 (ja) | 2017-03-24 | 2022-04-08 | 全薬工業株式会社 | 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体 |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| TWI822728B (zh) | 2018-01-31 | 2023-11-21 | 加藤元一 | 含有il-6抑制劑的哮喘治療劑 |
| CN113508140B (zh) | 2019-02-28 | 2024-11-19 | 学校法人顺天堂 | 与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药 |
| TWI868126B (zh) | 2019-04-17 | 2025-01-01 | 國立大學法人廣島大學 | 以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑 |
| JP7684656B2 (ja) | 2019-06-11 | 2025-05-28 | 小野薬品工業株式会社 | 免疫抑制剤 |
| CN115379858A (zh) | 2020-04-06 | 2022-11-22 | 光爱科技公司 | 用于杀死肿瘤细胞的医药品 |
| EP4190354A4 (en) | 2020-07-28 | 2024-12-04 | Chugai Seiyaku Kabushiki Kaisha | Prefilled syringe preparation with needle, provided with needle shield and including novel modified antibody |
| EP4205764A4 (en) | 2020-08-27 | 2024-10-30 | Juntendo Educational Foundation | BISPECIFIC ANTIBODY CALR-CD3 MUTANT ANTI-TRUNCATED AND PHARMACEUTICAL COMPOSITION |
| US20240158518A1 (en) | 2021-03-12 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment or prevention of myasthenia gravis |
| WO2023057871A1 (en) | 2021-10-04 | 2023-04-13 | Novartis Ag | Surfactant stabilizers |
| KR20240011866A (ko) | 2021-12-01 | 2024-01-26 | 추가이 세이야쿠 가부시키가이샤 | 항체 함유 제제의 조제 방법 |
| KR20240155885A (ko) | 2022-02-25 | 2024-10-29 | 각코우호우진 쥰텐도 | 항변이 calr 항체와 다른 약제를 조합하여 이루어진 의약 |
| WO2025198912A1 (en) | 2024-03-21 | 2025-09-25 | Hoffmann-La Roche Inc. | Methods of treating myasthenia gravis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1982001461A1 (en) * | 1980-07-18 | 1982-05-13 | Leland Stanford Junior Univ | Human hybridomas,precursors and products |
| NZ198851A (en) * | 1980-11-07 | 1984-07-31 | Wistar Inst | Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line |
-
1982
- 1982-05-21 JP JP57084843A patent/JPS58201994A/ja active Granted
-
1983
- 1983-05-19 CZ CS833566A patent/CZ280677B6/cs not_active IP Right Cessation
- 1983-05-19 SK SK3566-83A patent/SK279249B6/sk unknown
- 1983-05-20 WO PCT/US1983/000781 patent/WO1983004313A1/en not_active Ceased
- 1983-05-20 AT AT83902157T patent/ATE114189T1/de not_active IP Right Cessation
- 1983-05-20 AU AU17729/83A patent/AU560595B2/en not_active Expired
- 1983-05-20 HU HU832697A patent/HU190908B/hu not_active IP Right Cessation
- 1983-05-20 JP JP58502264A patent/JPS60501359A/ja active Pending
- 1983-05-20 EP EP83902157A patent/EP0109441B1/en not_active Expired - Lifetime
- 1983-05-20 DE DE3382764T patent/DE3382764T2/de not_active Expired - Lifetime
- 1983-05-23 ZA ZA833686A patent/ZA833686B/xx unknown
- 1983-05-31 IN IN683/CAL/83A patent/IN157982B/en unknown
-
1984
- 1984-01-19 FI FI840219A patent/FI86077C/fi not_active IP Right Cessation
- 1984-01-20 DK DK025084A patent/DK164510C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI840219L (fi) | 1984-01-19 |
| DK25084D0 (da) | 1984-01-20 |
| AU1772983A (en) | 1983-12-16 |
| DK164510C (da) | 1992-11-23 |
| IN157982B (enExample) | 1986-08-09 |
| ZA833686B (en) | 1984-09-26 |
| JPS60501359A (ja) | 1985-08-22 |
| JPS58201994A (ja) | 1983-11-25 |
| JPH0159878B2 (enExample) | 1989-12-20 |
| DK164510B (da) | 1992-07-06 |
| EP0109441B1 (en) | 1994-11-17 |
| FI840219A0 (fi) | 1984-01-19 |
| CZ280677B6 (cs) | 1996-04-17 |
| DK25084A (da) | 1984-01-20 |
| DE3382764D1 (de) | 1994-12-22 |
| SK356683A3 (en) | 1998-08-05 |
| WO1983004313A1 (en) | 1983-12-08 |
| AU560595B2 (en) | 1987-04-09 |
| FI86077B (fi) | 1992-03-31 |
| CZ356683A3 (en) | 1995-11-15 |
| SK279249B6 (sk) | 1998-08-05 |
| EP0109441A4 (en) | 1986-09-22 |
| HU190908B (en) | 1986-12-28 |
| ATE114189T1 (de) | 1994-12-15 |
| FI86077C (fi) | 1992-07-10 |
| EP0109441A1 (en) | 1984-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3382764T2 (de) | Humane-humane hybridomas für neoplasmen. | |
| DE69128253T2 (de) | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen | |
| DE3686187T2 (de) | Monoklonale choriokarzinom-antikoerper und antikoerpergarnitur. | |
| DE3586440T2 (de) | Zur diagnose von menschlichem magen- oder brustkrebs zu verwendender monoklonaler antikoerper. | |
| DE3586262T2 (de) | Monoklonale antikoerper und antigen fuer menschliche lungenkarzinome vom nichtkleinen zellentyp. | |
| DE3883803T2 (de) | Monoklonale Antikörper gegen melanoma-assoziierte Antigene, Hybridzellinien, die diese Antikörper produzieren, und ihre Verwendung. | |
| DE3887675T2 (de) | Antikörper. | |
| DE69230890T2 (de) | Bestimmung von nukleären matrixproteinen in flüssigkeiten | |
| AT400577B (de) | Verfahren zur herstellung eines monoklonalen antikörpers und verfahren zum nachweisen von malignen zellen | |
| EP0260610A2 (de) | Monoklonale Antikörper gegen humanen Tumonekrosefaktor (TNF) und deren Verwendung | |
| DE3301249A1 (de) | Verfahren zur herstellung von humanen monoklonen antikoerpern | |
| EP1805221B1 (de) | Monoklonaler antikörper gegen humanen frizzled-4-rezeptor | |
| DE4107154A1 (de) | Monoklonale antikoerper gegen melanom | |
| DE3780480T2 (de) | Test fuer menschlichen brustkrebs. | |
| DE3851571T2 (de) | Krebsbezügliche antigenspezifische menschliche Immunoglobuline und menschliche-menschliche Hybridome, die diese menschlichen Immunoglobuline produzieren können. | |
| DE69033457T2 (de) | Prohormonspaltungsplatzblockierungsantikörper | |
| DE3884646T2 (de) | Humanes Karcinom-assoziertes Antigen und an dieses Antigen bindende Antikörper. | |
| DE19727814C1 (de) | Anitkörper 4G8B4B12 | |
| KR880001567B1 (ko) | 경부암을 위한 인체-인체융합세포 | |
| EP0955361A1 (de) | Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstelung sowie ihre Verwendung | |
| EP0537489B1 (de) | Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE69434024T2 (de) | Auf humanen cortikalen thymozyten exprimierte oberflächenproteine und ihre verwendung | |
| DE69633976T2 (de) | Monoklonale antikörper und antigene mit bezug zum menschlichen lungenadenokarzinom und immunoassay-verfahren unter verwendung desselben | |
| DE4110405A1 (de) | Verfahren zum nachweis der differenzierung und der invasivitaet von karzinomzellen | |
| EP0854152B1 (de) | Antikörper und immunoassay zum Nachweis von MIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |